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Abstract:
Introduction : Despite evidence of the efficacy of Adjuvant Endocrine Therapy (AET) in 
reducing the risk of recurrence and mortality after treatment for primary breast cancer, 
adherence to AET is suboptimal.  This study aimed to explore factors that influence 
adherence and non-adherence to adjuvant endocrine therapy (AET) following breast cancer to
inform the development of supportive interventions.   
Methods: Interviews were conducted with 32 women who had been prescribed AET, 2-4 
years following their diagnosis of breast cancer,.  Both adherers (n=19) and non-adherers 
(n=13) were recruited.  The analysis was conducted using the Framework approach.
Results: Factors associated with adherence were: Managing side effects including 
information and advice on side effects, and taking control of side effects, Supportive 
relationships, and Personal influences.  Factors associated with non-adherence were: Burden 
of side effects, Feeling unsupported, Concerns about long term AET use, 
Re-gaining normality, including valuing quality of life over length of life, and Risk 
perception
Conclusions: Provision of timely information to prepare women for the potential side effects 
of AET and education on medication management strategies are needed, including provision 
of timely and accurate information on the efficacy of AET in reducing breast cancer 
recurrence, and on potential side effects and ways to manage these should they arise.  .    
Trust in the doctor-patient relationship and clear patient pathways for bothersome side effects 
and concerns with AET are important.  Training and education around AET for GPs should be
considered alongside novel care pathways such as primary care nurse cancer care review, and
community pharmacist follow-up.
Key words:
Adherence to adjuvant endocrine therapy; Breast Cancer; Patient Experiences;
Support & Follow-up
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1. Introduction
Breast cancer is the most common cancer among women worldwide.1  Approximately 55,000 
women in the UK are diagnosed every year and one in five of these women will experience a 
recurrence at some point following primary treatment.2,3  Adjuvant endocrine therapies (AET)
such as tamoxifen and aromatase inhibitors (AIs) have proven clinical benefit, reducing the 
risk of recurrence for women with oestrogen receptor positive (ER +ve) breast cancer by 
11.8% and mortality by 9.2% over five years.4  Guidelines until recently recommended five 
years of treatment but, following trial evidence, this is being extended to 10 years.5-9 
Despite the known efficacy of adjuvant endocrine therapy (AET),5-9 adherence to AET is 
suboptimal. In a systematic review of 29 studies, adherence to AET over five years ranged 
from 41% to 72%.10  Previous studies have reported that fewer than 50% of women complete 
a full five years of AET, leading to increased recurrence and a 20% rise in breast cancer 
mortality, as well as higher medical costs and poorer quality of life.11-13  As the time to 
discharge from routine follow-up decreases and the recommended time to take AET increases
to 10 years, adherence rates could be expected to fall further. 
While previous quantitative studies have identified factors associated with non-adherence to 
AET, including side effects, lack of knowledge about AET, and medication beliefs,14-16  only 
limited qualitative research has been conducted in this area.17,18  In order to develop patient-
centred interventions and guide clinical practice to improve medication adherence, a thorough
understanding of women’s perspectives on this topic is essential.19 
Using interviews with women, this study aimed to explore, in depth, the factors that influence
whether women adhere to or do not adhere to AET to  inform the development of 
interventions to improve adherence, and ultimately to improve outcomes for women who 
have been treated for breast cancer.
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2. Methods
A sample of women who had been prescribed AET following treatment for breast cancer 
were recruited two to four years after initiating treatment.  The sample included both adherers
and non-adherers:  
 Adherers were defined as still taking the medication as recommended.  
 Non-adherers were defined as having initiated AET but now had stopped taking the 
medication.  
Participants were identified and recruited through two sources.  Initially, women who had 
taken part in a previous questionnaire survey (n=292) and reported adherence or non-
adherence to AET were asked if they would participate in an interview.14 As the number of 
non-adherers recruited from this source was small (n=5), a second group of women who self-
reported non-adherence to AET was recruited through one month advertisements on two UK 
charity website forums: Independent Cancer  Patients’ Voice and Breast Cancer Care (n=8). 
Semi-structured interviews were conducted by JB either at the woman’s home or at another 
place of her choice.  Interviews lasted between 41 and 103 minutes (mean 60 minutes).  All 
interviews were digitally recorded and transcribed verbatim.
Analysis was carried out using the Framework approach with adherers and non-adherers 
analysed as two separate groups.20   JB read all the transcripts and both MB and EW read a 
selection of the same transcripts in order to gain an overview of the women’s accounts and 
identify recurring themes. This led to the development of a coding framework.  Two 
transcripts from each group were coded by at least two of the authors.  Coded transcripts 
were compared and codes further refined and then grouped together into broader categories.  
The Framework approach allows both inductive and deductive analysis.20  Codes and 
categories were therefore derived both inductively from the women’s accounts and 
deductively from relevant literature, for example, the Necessity-Concerns Framework 
developed by Horne et al.21,22 
The coding framework was then applied to index the transcripts, that is, a code was attached 
to each relevant passage of text using the software NVivo 10.  JB coded all interviews, and 
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MB coded one from each group to assess consistency.  When indexing was complete, a 
matrix was created, with a page for each category and one code per column and one 
participant per row.  For each participant, data were abstracted for each code and summarised
in the appropriate cell on the matrix, with notes of supporting quotes.  The matrix was then 
reviewed in relation to the research questions and themes generated by making comparisons 
and looking for connections across cells, both within and between participants.  Interpretation
of the data is reported here using relevant quotes to illustrate.
3. Results:
Interviews were conducted with 32 women, all of whom had been prescribed AET after 
treatment for primary breast cancer.  Participants include 19 adherers and 13 non-adherers 
from England and Wales.  Characteristics of the sample are shown in table 1 below. 
 3.1. Table 1: Characteristics of sample 
 Adherers (n=19) Non-adherers (n=13)
Recruitment method:
Questionnaire survey
UK Charity forums
19
0
5
8
Age:
Range
Median
 
37-77 years
59 years
 
53-76 years
64 years
Marital status:
Married
Single
Separated
Widow
 
15 (79%)
1   (5%)
 
3   (16%)
 
10 (77%)
2   (15%)
1   (8%)
Education:
‘O’ level, GCSE, or equivalent
‘A’level or equivalent
College or university degree, 
HND or HNC
1 (5%)
16 (84%) 9 (69%)
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Postgraduate qualification
Other
2 (11%) 4 (31%)
Type of AET
Tamoxifen
Aromatase Inhibitor
Swapped 
13 (68%)
3 (16%)
3 (16%)
6 (46%)
1 (6%)
6 (46%)
For those who continued to take their medication three key themes which facilitated 
adherence were identified.  For those who had discontinued their medication five key themes 
associated with non-adherence were identified.    
Factors associated with adherence to AET 
1) Managing side effects    
1.1 Information and advice
Receiving timely information and expert advice were important to participants.   Adherers 
valued timely and relevant information which they sought from a range of sources including 
health professionals, the internet, and/or other women taking AET.  Many would have liked 
more information in relation to side effects than they received: 
“I would have liked more information to prepare for the side effects.  I was given lots of 
information about the side effects of chemotherapy and how to manage them, but I wasn’t 
expecting the side effects of AET.  So perhaps that made it worse”
(P1 adherer)
For some adherers the source of information was also important and advice provided by a 
trusted doctor was particularly valued in guiding their behaviour:
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I wanted to know more about why I was taking it and he went into a lot of detail of how it 
works.  [If my doctor says] it reduces the risk of the cancer coming back, I’d be mad not to 
take it. (P19 adherer)
I must admit I take it – if they [doctors] say it’s a good idea I’m very much... I think because 
my experience has been so positive with them[doctors] I’ve not come away doubting 
anything.  (P2 adherer)
For others, lack of timely information had meant delay in attributing the side effects to AET 
lead to anxiety and concern about other conditions:
I thought it was the long-term effects of chemotherapy, so I thought it would improve.  When 
it didn’t long-term, I began to realise it was possibly the hormone therapy.(P17)
1.2 Taking control
Adherers seemed motivated to manage the side effects caused by AET and to take control 
over their bodies again.  Some had sought information from the internet or online forums on 
ways to adapt their lifestyle to help them tolerate their medication, such as changing their 
diet, increasing the exercise they took, decreasing their alcohol and caffeine intake, and also 
on coping strategies that helped alleviate side effects such as using ‘chill’ pillows, drinking 
iced water and wearing thin layers of clothes.
I read on the internet about looking after myself… I eat much healthier now, and avoid 
alcohol and caffeine.  A bit boring, but it helps. The side effects are less now. (P7-adherer)
The online forum had other women chatting about it…the ‘chill’ pillows are great at night – I
bought it online (P1-adherer)
I wanted to be able to do something for myself.  I wanted to be able to adapt and have some 
way of coping with the side effects. I started by eating more healthily. It was a way of taking 
back control. (P5 adherer)
2) Supportive relationships   
7
Adherers found supportive relationships from family and health professionals valuable in 
motivating them in continued use of AETs.  Some talked of supportive husbands, family or 
friends and how their support enabled them to carry on: 
He [husband] is brilliant.  He’s very understanding – he has been with me 100% through 
everything.  He has gone to hospital appointments with me but he just worries about how I 
feel (P6 adherer) 
Others described a positive and supportive relationship with their surgeon, oncologist or GP, 
whose care and concern encouraged continuation with the medication: 
I had a long conversation with him [GP] about it – he really cared.  He swapped me on to 
this one – I know he is doing what he can. If you feel someone cares, it kind of encourages 
you to keep going, if you know what I mean. (P18 adherer)
3.  Personal influences
Several adherers spoke of their responsibility towards others as important in their decision to 
continue taking AET.  Adherers who had young children at home talked of their adherence to 
AET in terms of their commitment to their children and their need to stay alive and healthy 
for their sake, whatever the cost to themselves.
 
“I will carry on despite how I feel just because it’s the only thing I can do and I’ll do 
anything I can because of the kids really –I do want to be around [for them]”(P1, adherer)
Similarly, another woman continued taking her medication for the sake of her husband whose
first wife had died of breast cancer, despite the weight gain she experienced and its impact on
her confidence to continue working as a health advisor:
I really didn’t want to take it [because of weight gain] and I have to say the only reason I 
have taken it, I think, it’s because of my husband.   Because he lost his first wife to breast 
cancer and I think I would be really selfish if I didn’t take it for him but if it had been me I 
might not have taken it (P6 - adherer) 
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For some women it was their previous experience of loss to cancer that influenced their 
decision.  Some adherers had experienced the loss of loved ones from cancer and this 
experience provided the motivation to continue with their medication.  They perceived AET 
as a potentially life-saving ‘safety net’, and were more likely to want to continue for ten 
years.  In the following examples, one woman had lost her mother after breast cancer 
recurred when she stopped taking tamoxifen, while the other woman had lost both her 
husband and colleague to cancer:
 “…[my mother’s] trouble started up again when she stopped the tamoxifen so I have got that
double idea that I’m safe while I’m on it”(P12 adherer)
My husband died of cancer in 2002… Then in 2006 . . . my colleague died and I was 
diagnosed in 2010. So that was just four years, so you do think ‘Oh my god, that’s your death
sentence’…you just want to take it for as long as possible (P8  adherer)
Factors associated with non-adherence to AET 
1) The burden of side-effects  
There was considerable heterogeneity in side effects described by non-adherers, and non-
adherers tended to perceive themselves as suffering more from the severity and impact of side
effects on their daily life than adherers.  These included hot flushes, weight gain, vaginal 
discharge or dryness, joint aches as well as tiredness, lack of energy, mood swings, and 
depression. Women described how these side effects had disrupted their day to day lives and 
interactions with others in ways they found difficult to manage.  Several women spoke of 
deep depression and mood swings, which they originally attributed to the stress of diagnosis 
and active treatment, but over time associated with AET. 
I turned into a monster over the few months following chemotherapy.  I thought it was the 
stress of what I had been through, but it went on and on.  I read on the internet that it could 
be the tamoxifen.  I felt depressed and would swing into a temper for no reason.
(P22 non-adherer)
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It [tamoxifen] altered my mind  . . . I felt almost suicidal with it.  I didn’t realise it was the 
drug until I got sick and didn’t take it for a week.  I felt so much better.
(P21 non-adherer)
Some side effects were described as frequent, severe and unpredictable, thereby restricting 
social activities and affecting friendships and relationships.  This also gave rise to a loss of 
confidence and loss of motivation in life, leading to social isolation.
And I didn’t want to go out and I became quite withdrawn really, so no, it wasn’t acceptable  
(P20- non-adherer)
I didn’t really feel like doing anything.  I carried on going to work, that was fine.  I just 
couldn’t be bothered to do anything out of work – like meet friends, see family.  I just wanted 
to vegetate at home (P24-non-adherer)
In some cases, side effects impacted on the women’s confidence to work.  One non-adherer 
described how her weight gain and body image had an impact on her role as a fitness 
instructor:
I knew quite a few and people who knew women who had put on a lot of weight which they 
blamed on the tamoxifen … How am I going to teach [aerobics] when I look like a balloon? 
…So that was a problem and that was all part of the hysteria (P27 non-adherer)
While women tried to hide their side effects and maintain normality, they were also aware 
that the side effects impacted on their partners and friends.
I got thrown into the menopause. … [O]ne of the things that upset me most at the time [was 
that]I lost all interest in sex overnight – it didn’t help my husband as you can imagine 
(P30 non-adherer)
I talk to my friends but not for very long and not in any detail partly because I don’t want 
[them] to think ‘I’m not going to bother seeing [name of participant] you know.’  – They are 
only going to go – ‘oh she’s depressed or something’. (P31 Non-adherer)
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Women were often unprepared for side effects. Initial information on AET was provided 
alongside other treatment plans just after diagnosis, but non-adherers struggled to absorb 
information on side effects at this time, as their attention was focused on active treatment.  As
a consequence, they were unprepared for the side effects of AETs and the impact on their 
lives.  
I am sure I’d been told but you are suddenly bombarded with so much information.  Not that 
people mean to do that but there is a lot to contend with at a time when you are not really 
taking it in (P21 non-adherer) 
If someone had said to me, these are the side effects that other women report – say 20% of 
women have this side effect, and if you get it come back and we can help you with it, then that
would have been great.  It’s a lack of information that’s the problem (p26 non- adherer)
2) Feeling unsupported  
Some non-adherers described ‘falling through the gaps’ in the health care system once they 
had been discharged from hospital, and were uncertain where to turn for support:
You have the hospital that dealt with the issue and then after you have come out of hospital 
it’s the GP but the GP just refers you back to the hospital.  So you have that triangle...they 
forget to look at you as a whole person… They are only interested in their own department 
(p25 non-adherer)
Many non-adherers appeared unaware that their follow-up care had been transferred from the 
hospital to the GP.  There was limited contact with their GPs as, despite ongoing prescriptions
coming from their primary care practice, most women ordered their prescriptions online or 
over the phone and collected them from their local pharmacy.  In addition, they were not 
confident that their GP had appropriate expertise regarding their AET and preferred to contact
the hospital if they had any issues to discuss. 
Don’t get me wrong.  My GP is lovely.  But they don’t know much about treatments for breast 
cancer.  I’d rather talk to someone at the hospital (P22 non-adherer)
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Similarly, while most described their relationship with the breast care nurses (BCNs) as 
supportive and caring, they felt the BCNs had limited time and had to prioritise support for 
women in having surgery, or on chemotherapy or radiation treatment.  They therefore 
hesitated to ask them for advice around AET.
The breast care nurses were lovely, but rushed off their feet.  You didn’t want to disturb them 
unless it was life or death, if you know what I mean.  They had a lot of people to see who had 
far greater problems than me (P23 non-adherer)
Women felt health professionals were being conservative about what they told them.  One 
woman spoke of how the lack of interest and support in how she was dealing with side effects
had led her to discontinue using the drug. 
They are cautious with the amount of information they give you.  You can tell they are not 
telling you everything.  I can understand why they do this, but I would have preferred more 
information.(P31 non-adherer)
They answer questions but very much within their own confines (P27 non-adherer)
I just took myself off it so obviously I felt that nobody was interested – I think there needs to 
be follow-up for hormone therapy (P31 – non-adherer)
3)  Concerns about long-term AET use  
Non adherers were often sceptical of the benefits of AET, and concerned about its toxicity.  
The following woman, for example, felt there was little to be gained from taking the 
medication long-term, once she had been free of cancer for two years:   
I’d taken it for 2 years.  I’d given it a go.  It’s been two years since the breast cancer – I feel 
back to normal now, I don’t think it will make much difference now.(P20 – non-adherer)
Another had stopped taking AETs because of her concern for the way they had affected her 
physically. 
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It scared me what it did to me… I felt that I was drying up from the inside…I think my vision 
went slightly blurry and I felt older with aches and pains…dry skin and even felt that my 
teeth were slightly loose (P29 non-adherer)
For some non-adherers their general concerns about taking any medication long-term 
underpinned their decision to discontinue medication.  
I just don’t like taking medication – I never take headache tablets  I think in the long run they
are all harmful (P27 non-adherer)
4)  Re-gaining normality  
Most non-adherers had stopped taking their medication one to two years after taking it as 
prescribed.  For some, their initial non-adherence was not based on a conscious decision but 
happened unintentionally.  However, once the precedent had been set, and the consequences 
had been perceived as a welcome relief from the grind of taking them or the burden of side 
effects, periods of temporary suspension and then a permanent discontinuation tended to 
follow.  
I stopped taking them for a couple of weeks while I was on holiday.  I’d not taken them 
before, when I had flu for a week, and realised I felt better not taking them.  So I wanted to 
enjoy my holiday.  Get away from the grind of taking them.  I just never went back to them.  I 
meant to, it was just the longer I didn’t take them … (P23 Non-adherer)
Some women described ‘wanting to feel better’ and not wanting to feel ‘ill’ anymore and 
welcomed the release that stopping their medication brought.  There was a sense that the side 
effects of the drugs prevented them from getting back to normal life.
It just stops you getting on with your life.  You have been through surgery, then 
chemotherapy, then you take the hormone drugs.  You get to the stage when you want to get 
back to normal, but these drugs stop you doing that (P25 Nonadherer)
Valuing quality of life over length of life emerged as important for some.  For these women 
the importance of a good quality of life for their remaining years, with no side effects of AET,
outweighed the risk of recurrence, and provided a justification for stopping their medication.
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I keep thinking OK – you’re 73 and it’s interesting when you are old what it is … You want to 
enjoy the life you have left.  You don’t want to be on medication that makes you suffer and 
then die (p21 non-adherer)
I think you need to take life by the horns.  You make that decision and take the consequences. 
I took the decision not to continue because I wanted my normal life again.  It is about 
weighing up what is important to you, not the doctor (p26 non adherer)
5)  Risk perception and understanding risk  
Women perceived their risks of recurrence differently.   Several of the non-adherers believed 
they were at low risk of the cancer recurring.  Statistics were  complex and some women 
found them difficult to understand, and there was a misconception around whether they really
needed to continue with AET.
It’s a difficult one, but I feel it isn’t making that much difference to me because I’m low risk 
anyway (P28 non-adherer)
I was Stage 2,  so I wasn’t super high risk and I wasn’t super low risk – moderate.  If I had 
been higher risk would it have changed …a high risk of it coming back could have been 
different (P23 Non-adherer)
One women felt the doctor changed the statistics in an effort to persuade her to adhere to 
AET, causing confusion and distrust with the doctor
 
I think he said look you are 20% better off on this – you are 20% less likely for it to 
comeback and I questioned it a bit – and I said I don’t want to take it – but he said but you’re
40% better off when you take it – but I thought of saying but you didn’t say that last time – to 
be fair well you know these are statistics –statistics can trick you – you can prove anything 
with statistics – and then when I really thought I really don’t want to do this and he went Oh 
and the statistics went the other way – and he said you’re only 10% better off anyway (p27 
Non-adherer)
Discussion
This qualitative study explored factors influencing adherence to AET in women with early 
stage breast cancer.  Factors that influenced continued adherence included provision of timely
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expert information about AET, self-efficacy to manage side effects, and supportive 
relationships with health professionals and family members. Doing everything possible to 
reduce the risk of recurrence for the sake of family members, and fear generated from past 
experience of cancer were also strong drivers promoting adherence. Women who had 
discontinued AET described more burdensome side-effects, held more negative beliefs about 
the effectiveness of AET, perceived continuing AET as a barrier to regaining normality in 
their lives and placed a greater value on quality of life over quantity of life. In comparison to 
women who continued with treatment, they also seemed to feel less supported by health care 
professionals.  
Understanding why people adhere or do not adhere to prescribed medication is a complex 
issue. A recent meta-analysis of medication adherence in 22 different chronic diseases reports
that across the range of included studies, higher adherence was associated with stronger 
perceptions of necessity of treatment, and fewer concerns about treatment.21  The necessity-
concerns framework hypothesises that if concerns about medication outweigh the perceived 
necessity of taking the medication, then non-adherence is likely, and if the perceived 
necessity to take the medication outweighs the concerns, adherence is likely.22  This 
framework has previously been used to assess the beliefs and perceptions of treatment for 
breast23-25 and other cancers.26,27   Women in our study often appeared to weigh up their beliefs
about AET and their fears of recurrence alongside their experiences of the treatment and its 
impact on their daily lives, to inform whether they adhere or not, and thus our findings fit 
well with this theoretical framework.   
Our findings are consistent with, and add depth to previous quantitative studies, including our
own, which have addressed this topic.14,15  There have been only two previous qualitative 
studies conducted in this area.17,18  Harrow’s (2013) study focussed mainly on the experiences 
of women who were adherers to AET.17  The burden of side effects was reported and the 
study concluded that the advice, support and monitoring needed for adherence are not 
routinely offered in conventional follow-up settings.  Cahir (2015) interviewed both adherers 
and non-adherers in Ireland.18   This study identified modifiable influences on hormonal 
therapy medication taking behaviour including barriers and enablers to AET across three 
strata: beliefs about consequences, medication use, intentions and goals, and behaviour 
regulation.  Our findings are consistent with, and add weight to, the findings from these two 
studies. 
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Non-adherers in our study reported that a desire to feel ‘normal’ again led to discontinuation 
with AET.   A previous study found that while 90% of women adhered to AET in the first 
year, this figure dropped to 50% by the fifth year.11 Non-adherence may therefore coincide 
with a false sense of security of being ‘better’ or a sense of returning to normality over time 
that may tip the balance of the necessity-concerns framework described by Horne (1999), 
leading to non-adherence.22 It may also coincide with declining belief in the efficacy of 
hormonal therapy; this is consistent with findings from previous quantitative studies which 
found that negative beliefs in the effectiveness of AET can influence non-adherence.14,15  
Studies report that in chronic diseases prioritization of the importance of medication intake 
declines over time combined with issues of medication being seen as a reminder of the 
patients’ condition at a time when they are feeling well again and ongoing medication makes 
the person feel old or bad about themselves.28  As this study reports, permanent 
discontinuation often follows an unintentional period of temporary suspension, such as illness
or forgetting to take tablets away with them.  The feeling of normality during the temporary 
suspension can lead to intentional discontinuation. 
Our findings have a number of implications for practice (see Box 10).  Firstly, it is important 
that women receive timely information and discussion around AET in order that they 
understand the benefits of taking AET as prescribed, to ensure they are adequately prepared 
for side effects that may occur, and that they are equipped with coping strategies and 
information on where to seek support either through professional channels or other forms of 
support. The importance of well-timed information within the cancer trajectory has been 
widely recognised as important.29-31  A lack of adequate preparation for the impact of side 
effects has been shown to have a negative psychological response to cancer treatments. 
Where patients receive good preparation and education from health professionals, this 
empowers and enables them to cope better.32 
Providing clear explanations of benefits and risks associated with taking and not taking AET 
is also important.33  This is often not clearly communicated by health professionals.  The 
challenge is to continue trying to improve risk communication in health care, turning data 
into something more meaningful, relevant, and useful for individual patients. This could be 
achieved by adopting simple and practical strategies such as decision aids, tailored 
information and consultation summaries informed by the best available evidence base.34 
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It is important for women to be able to discuss the potential difficulties of remaining adherent
with long-term therapy, and for health professionals to provide information and instil 
confidence in long-term management of hormone therapy.35  Health professionals should 
follow a patient-centred-approach to care that promotes active patient involvement in 
management and coping strategies around AET which in turn empowers women to take 
control of their medication regime.36  Problem solving techniques or cognitive behavioural 
techniques have potential to overcome the barriers to adherence, and may improve 
communication channels with health professionals.37  Increased communication and trust with
the doctor-patient relationship increases willingness to accept medical advice and adherence 
to long-term preventative regimens such as AET.38-41  Studies show that the majority of 
patients still prefer to interact with health care professionals rather than gain information 
online or receive a booklet 34,42  In this study women suggested the need for follow-up 
specific to AET to provide support, give reassurance and prompt discussion of any issues 
arising.   
Our findings also suggest that possible avenues for support for women concerned about AET 
were poorly signposted and women were unclear whom they should contact. Specialist breast
care nurses are a point of contact for these women, but once discharged women no longer 
perceive it as the nurse’s role. Long term follow-up is with the GP and thus GPs have a 
potentially important role to play, especially as the length of hospital follow-up decreases and
the recommended duration of AET increases.  While adherers in our study were generally 
quite positive about the GP relationship, non-adherers were more ambivalent and critical of 
their specific knowledge.  This highlights the importance of ensuring GPs are educated 
regarding the issues experienced by women taking AET so they can provide more accurate 
information and support and encourage adherence.  Even following a period of non-
adherence GPs could have an important role in helping women understand that restarting may
still be beneficial.43  Alternatively, novel pathways could be explored, such as a nurse led 
discharge intervention, a primary care nurse cancer care review, or a community pharmacist-
led intervention.  
Strengths and Limitations:
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The qualitative methods of inquiry used in this study provided richer and more detailed 
information about adherence behaviours, and opportunities and interventions to improve 
adherence to AET.  The inclusion of a sample of non-adherers as well as adherers is a 
particular strength.  Although our participants varied in terms of socio-demographic 
characteristics and presented a range of views, we weren’t able to recruit from the black and 
minority ethnic groups, and the adherers had a greater age range and education to the non-
adherers.  It should also be note that a large proportion of women in our sample were on 
Tamoxifen, and that the experiences of women on Aromatase Inhibitors may be different and 
under-represented in our sample.  For example joint pain is a recognised side effect of AIs 
(add ref) which was not reported by women in our study.  Furthermore, as with all qualitative 
studies, the small sample size and the purposive sampling strategy mean that the results may 
not be generalizable to a wider population.  However, qualitative study designs provide 
depth, insight and identify nuances that may not have been identified through other methods, 
and help inform the acceptability and provide patient centred approaches to the developing 
interventions.
Conclusions
Improving adherence to AET will reduce recurrence of and mortality from breast cancer.  
However, medication-taking behavior is complex and involves patient, health professional, 
and process components.  Medication adherence is not exclusively the responsibility of the 
patient.  This qualitative study has provided an in-depth description of factors which can 
influence adherence to AET, and points to interventions that could assist in improving 
adherence.  These include the provision of timely information on efficacy of AET, preparing 
expectations around side-effects, and providing information and support on how to manage 
burdensome side effects.   Good communication and trust between the health professionals 
and the patient is important.  Doctors should follow a patient-centred approach to care that 
promotes active patient involvement in the decision–making process around AET. Training 
and education around AET for GPs should be considered, and novel care pathways to help 
manage the medication, such as primary care nurse cancer care review, and community 
pharmacist follow-up, should be explored. 
18
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